Many vaccine companies have witnessed rapid growth in 2017 performance

Pharmaceutical Network March 7 hearing

The performance of Zhifei Biological, Kangtai Biological, and Changsheng Biological has grown significantly. Among them, Zhifei Bio's net profit soared 12 times.

Zhifei Biometrics Express reported that in 2017, operating income was 1.343 billion yuan, a year-on-year increase of 201.06%; net profit was 432 million yuan, an increase of 1229.25% compared to the same period of last year. For the reasons for the significant increase in performance, Zhifei Bio indicated that during the reporting period, Uncertainties such as changes in industrial policies triggered by the '18 August Vaccine Industry Incident' are gradually being eliminated, the new industry policy is gradually implemented, the industry environment is further standardized, and the company’s own products and agents are used to promote and sell Class II vaccine products. One after another resume.

In addition, Kangtai Biology and Longevity respectively achieved operating revenue of RMB1.164 billion and RMB1.553 billion in 2017, up 110.95% and 52.60% over the same period of previous year respectively; net profit was RMB217 million and RMB565 million respectively, up 152.32% and 32.95% respectively over the same period of last year, .

Watson creature is in a huge loss, but its net profit contributed by independent vaccine products increased significantly.The announcement shows that Watson biological independent vaccine sales in 2017 generated operating income of 515 million yuan, an increase of 292 million over the same period the previous year Yuan, an increase of 130.99%; net profit increased 80.660 million yuan over the previous year, an increase of 625.20%.

Even if faced with a performance change, Watson’s stock price has not been weak. Dongxing Securities believes that Watson’s biometrics will see rapid growth as the first heavy-weight 13-pill pneumonia vaccine will be launched in late 2018 and early 2019.

According to the China Securities Journal reporter, the 13-valent pneumonia vaccine for our infants Toddler Invasive pneumococcus disease Has significant clinical value. The 13th pneumonia vaccine researched by Watson Bio is the second in the world. Combined with Pfizer's 2016 global sales of US$5.7 billion in a single product of 13-valent pneumonia vaccine, many brokerages believe Watson Bio The price of the 13-valent pneumonia vaccine will be expected after the big market, bringing huge performance increase for the company.

In addition, Watson’s Bivalent HPV vaccine for cervical cancer, Herceptin for breast cancer, and Grams for the treatment of arthritis are all in Phase III clinical stages. The industry’s predicted time to market is around 2020. In the future, any variety will be listed and the company's performance will grow rapidly.

In terms of Chi Feibi, it owns the recently-listed Merck East 4-valent HPV vaccine (cervical cancer vaccine) and the pentavalent rotavirus vaccine (a vaccine against rotavirus enteritis). It is the sole agent in China. According to Chinese food drug According to data from the Institute of Verification and Testing, the number of approvals for the Merck 4 price HPV vaccine in January 2018 is approximately 600,000. In addition, the pentavalent rotavirus vaccine is currently included in the priority review, and the industry is expected to be approved for listing in 2018.

Exclusive proxy In addition to the heavy pharmaceuticals, Zhifei Bio has a rich variety of on-going research varieties. It has several clinical trials for the diagnosis and prevention of tuberculosis. Phase III clinical trials have been completed, mainly including preventive micro-cards, EC diagnostic reagents, etc. At the beginning of 2019, it will be marketed. At the same time, the freeze-dried Hib vaccine (Haemophilus influenzae type b vaccine), 15-valent pneumonia vaccine and freeze-dried human rabies vaccine independently developed by Zhifei Bio have also obtained clinical approvals in succession.

Many new breeds of Contac biological will also be listed one after another or have a significant impact on the performance of listed companies in the future, of which, the 23-valent pneumococcal vaccine and the third generation rabies vaccine-lyophilized human rabies virus vaccine are currently in the pre-market inspection Stage.China Southwest Securities expects the two varieties will be listed in 2018, is expected to contribute about 100000000 yuan and 500000000 yuan of net profit.In addition, Kangtai biological 13 pneumococcal vaccine is currently in phase Ⅲ clinical.According to Southwest Securities estimates , Kangtai biological 13-valent pneumonia vaccine will be listed in 2020, for the net profit of listed companies or over one billion yuan.